Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cidara Therapeutics Inc    CDTX

CIDARA THERAPEUTICS INC (CDTX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
3.75(c) 4.1(c) 4(c) 3.85(c) 3.9(c) Last
146 256 254 597 129 988 164 215 222 642 Volume
-3.85% +9.33% -2.44% -3.75% +1.30% Change
More quotes
Financials (USD)
Sales 2018 0,51 M
EBIT 2018 -63,7 M
Net income 2018 -64,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 1,10 M
EBIT 2019 -65,8 M
Net income 2019 -65,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 159x
Capi. / Sales2019 73,6x
Capitalization 81,0 M
More Financials
Company
Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections.Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J.... 
More about the company
Surperformance© ratings of Cidara Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CIDARA THERAPEUTICS INC
04/12CIDARA THERAPEUTICS : to Present Rezafungin Data at the European Congress of Cli..
AQ
04/04CIDARA THERAPEUTICS : to Present Rezafungin Data at the European Congress of Cli..
BU
03/22CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Other Events
AQ
03/22CIDARA THERAPEUTICS : Provides Clinical Data Updates for its Lead Antifungal Rez..
AQ
03/21Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Re..
GL
03/20CIDARA THERAPEUTICS : antifungal passes mid-stage human testing, but shares plum..
AQ
03/19CIDARA THERAPEUTICS, INC. (NASDAQ : CDTX) Files An 8-K Regulation FD Disclosure
AQ
03/19Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Tria..
GL
03/08Cidara Therapeutics to Present Rezafungin Data at the European Society for Bl..
GL
03/01Cidara Announces Appointment of Chrysa Mineo as Independent Director
GL
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/18Want automatic email alerts for $ETSY $VIRT $CDTX $KMPH $BIO? Subscribe to Ma.. 
04/17TREND REVERSAL UP ALERT: $CDTX CIDARA THERAPEUTICS ? TradeIdeas via  
04/05Cidara Therapeutics $CDTX Given Average Recommendation of “Buy” by Brokerages.. 
04/04Cidara Therapeutics to Present Rezafungin Data at the European Congress of Cl.. 
04/04Cidara Therapeutics to Present Rezafungin Data at the European Congress of Cl.. 
More tweets
Qtime:84
News from SeekingAlpha
04/13Key events next week - healthcare 
03/21CIDARA : Can The Market Be That Stupid? 
03/20U.S. BIOTECH/PHARMA SECTOR DAILY OBS : March 19, 2018 
03/20Cidara Should Be On Your Radar After Positive Phase 2 Despite The Drop In Sha.. 
03/20YOUR DAILY PHARMA SCOOP : Heron's HTX-011, Geron Update, Cidara Tumbles 
Chart CIDARA THERAPEUTICS INC
Duration : Period :
Cidara Therapeutics Inc Technical Analysis Chart | CDTX | US1717571079 | 4-Traders
Technical analysis trends CIDARA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 15,3 $
Spread / Average Target 293%
EPS Revisions
Managers
NameTitle
Jeffrey L. Stein President, Chief Executive Officer & Director
Scott M. Rocklage Chairman
Matthew W. Onaitis CFO, Secretary, CAO & General Counsel
Taylor Sandison Chief Medical Officer
Theodore R. Schroeder Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CIDARA THERAPEUTICS INC-42.65%81
GILEAD SCIENCES2.88%98 675
VERTEX PHARMACEUTICALS5.53%41 476
REGENERON PHARMACEUTICALS-15.99%34 613
GENMAB24.15%12 833
BEIGENE LTD (ADR)71.91%9 059